IMUNON Phase 2 OVATION 2 Study Shows 11.1-Month Improvement in Overall Survival

Tuesday, 30 July 2024, 12:02

IMUNON has released promising results from its Phase 2 OVATION 2 study, highlighting an impressive **11.1-month increase in overall survival** for patients receiving **IMNN-001** alongside standard-of-care chemotherapy. The study yielded a **hazard ratio of 0.74**, indicating a notable reduction in the risk of death. These findings position IMUNON's treatment as a potentially pivotal development in cancer therapeutics, advocating for its further evaluation and adoption in clinical practice.

Globenewswire — IMUNON Phase 2 OVATION 2 Study Shows 11.1-Month Improvement in Overall Survival

OVATION 2 Study Results

The Phase 2 OVATION 2 study conducted by IMUNON has reported a remarkable 11.1-month increase in overall survival for patients treated with IMNN-001 in conjunction with standard chemotherapy.

Key Findings

Hazard ratio reported at 0.74, suggesting a lower risk of mortality.
The treatment has shown promising efficacy in the first-line setting.
Results underscore the potential of IMNN-001 in improving patient outcomes.

Conclusion

The findings from the OVATION 2 study highlight the significant benefits of incorporating IMNN-001 into standard treatment protocols, indicating a need for further clinical exploration.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

OVATION 2 Study Results

Key Findings

Conclusion

Related posts